. 2022 Sep 23;16(21):3855–3880. doi: 10.1002/1878-0261.13312

Table 3.

Uses of senolytic drugs in preclinical models of cancer.

Class	Drug	Cancer	Senescence induction	Model
BH3 mimetics	ABT‐263/navitoclax	Breast cancer	Irradiation, paclitaxel	4226, Cal51 [201]
		Breast cancer	Doxorubicin	MDA‐MB‐231, MDA‐MB‐231 xenograft [202]
		Colorectal cancer	Etoposide	HCT‐116 [203]
		Glioblastoma	Irradiation	GBM39, GBM76, GBM6, GBM123 [204]
		Glioblastoma	Temozolomide	GBM39, GBM76 [204]
		Lung cancer	Etoposide, irradiation	A549, A549 xenograft [202]
		Breast, lung cancer, osteosarcoma	Doxorubicin	4226, SKBR7, Cal51, U2OS, A549 [201]
		Lung, breast, colorectal, hepatocellular cancers	Alisertib or etoposide	A549, MDA‐MB‐231, SUM159, RKO, PC9, MCF‐7, Huh7, Hep3B, H358, T47D, HepG2 [203].
		Ovarian and breast cancers	Olaparib	OV1946, OV4453, MDA‐MB‐231 [142]
	ABT‐199/venetoclax	Breast cancer	Palbociclib	MCF‐7, patient tumour organoid, PDX [205]
		Glioblastoma	Temozolomide	LN‐229 [206]
		Sarcoma	Irradiation	STS117, STS93, STS109 [207]
	ABT‐263/navitoclax + S63845 MCL‐1 inhibitor	Breast cancer	Doxorubicin	HCC712, MDA‐MB‐175, MCF‐7, 747D [201]
	ABT‐263/navitoclax + S63845 MCL‐1 inhibitor	Breast cancer	Irradiation, paclitaxel	MDA‐MB‐175 [201]
	S63845 MCL‐1 inhibitor	Prostate cancer	Docetaxel	PC3 Luc‐ShTimp1 xenografts [208]
Cardiac glycosides	Ouabain	Craniopharyngioma	Oncogenic β‐Catenin	Hesx1^Cre/+;Ctnnb1^lox(ex3)/+ mouse model [209]
		Colorectal cancer	Doxorubicin	HCT‐116 [209]
		Preneoplastic hepatocytes	NRAS^G12V expression	NRAS^G12V hydrodynamic injection in mice [209]
		Hepatocellular carcinoma, lung cancer	Etoposide, Barasertib, Alisertib, Tozasertib, Palbociclib	SK‐Hep1 and A549 [209] [210]
		Lung cancer	Etoposide, doxorubicin	A549 [210]
		Lung cancer	Bleomycin, Gemcitabine, Doxorubicin, Etoposide, Palbociclib	A549 [211]
		Melanoma	Palbociclib	SK‐MEL‐103 [211]
	Digitoxin	Hepatocellular carcinoma, lung cancer	Etoposide, Barasertib, Alisertib, Tozasertib, Palbociclib	SK‐Hep1 and A549 [209]
	Digoxin	Breast cancer	Doxorubicin	PDX [211]
		Lung cancer	Bleomycin	A549 [211]
		Lung cancer	Gemcitabine	A549 xenografts [211]
		Melanoma	Palbociclib	SK‐MEL‐103 [211]
	Proscillaridin A	Lung cancer	Bleomycin	A549 [211]
Galacto‐conjugates	Gal‐NP(Nav)	Breast cancer	Palbociclib	Xenograft [212]
	Nav‐Gal	Lung cancer	Cisplatin	A549 + xenograft [213]
	Galactose‐modified duocarmycin	Craniopharyngioma	Oncogenic β‐Catenin	Hesx1^Cre/+;Ctnnb1^lox(ex3)/+ [214]
BET inhibitor	ARV825	Colorectal carcinoma	Doxorubicin	HCT‐116 [215]
BET inhibitor	ARV825	Hepatocellular carcinoma		Obesity‐induced HCC mouse model [215]
HDAC inhibitor	Panobinostat	HNSCC	Taxol, cisplatin	FaDu, UMSCC47 [216]
HDAC inhibitor	Panobinostat	Lung cancer	Taxol, cisplatin	A549, H460 [216]
FOXO4 peptidomimetics		Melanoma	Doxorubicin	A375, A375 grafts [217]
mTOR inhibitors	AZD8055 and AZD2014	Hepatocellular carcinoma	XL413 (CDC7 inhibitor)	Huh7, Hep3B; Huh7 and MHCC97H xenografts; Myc^OE;Trp53^KO‐HCC bearing mice [147]